References

  1. Rosenthal J, Brown HL, Harris DT. Stem cell recovery following implementation of an automated cord blood processing system in a high volume laboratory. Biol Blood Marrow Transplant. 2008;14(2):42s.
  2. Kurtzberg J, Cairo MS, Fraser JK, et al. Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. Transfusion. 2005;45:842-855.
  3. Papassavas AC, Gioka V, Chatzistamatiou T, et al. A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused hematopoietic progenitor cells in adults. Int Jnl Lab Hem. 2007;1-9.
  4. Blind survey, Gfk Market Measures, 07/12, funded by CBR.
  5. Data on file.
  6. Sustain Lane. 2008 US City Ranking. Natural Disaster Risk. Available at http://www.sustainlane.com/us-city-rankings/categories/natural-disaster-risk. Accessed June 15, 2009.
  7. Praught M, Turner T, Brown H. Impact of Anticoagulant and Time from Collection to Processing on Cord Blood Cell Viability and Count. Cytotherapy. 2010;12(S1):46.
  8. Harris DT, McGaffey A, Brown H. The effect of collection bag anticoagulant on umbilical cord blood stem cell yield. Transfusion. 2008;48(s2):206A.
  9. Baumert B, Grymula K, Pietruszka D, et al. An optimization of hematopoietic stem and progenitor cell isolation for scientific and clinical purposes by the application of a new parameter determining the hematopoietic graft efficacy. Folia Histochem Cytobiol. 2008;46(3):299-305.
  10. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol. 2007;137(1):20-35.
  11. Scaradavou A, Stevens C, Dobrila L, et al. Cord Blood (CB) Unit Mononuclear Cell (MNC) Dose: Effect on Transplantation Outcome and Relevance to Processing Method and CBU Selection. Blood. 2008;112:1969.
  12. Fountain D, Ralston M, Higgins N, et al. Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion. 1997;37(6):585-591.
  13. In-house surveys, 2003 - 2011 includes customers who stated they were satisfied to extremely satisfied. Accessed 07/06/2011.
  14. Revoltella RP, Papini S, Rosellini A, et al. Cochlear repair by transplantation of human cord blood CD133+ cells to nod-scid mice made deaf with kanamycin and noise. Cell Transplant. 2008;17(6):665-678.
  15. Chang Y, Oh W, Choi SJ, et al. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Attenuate Hyperoxia-Induced Lung Injury in Neonatal Rats. Cell Transplantation. 2011;18:869-886.
  16. Lin YC, Ko TL, Shih YH, et al. Human Umbilical Mesenchymal Stem Cells Promote Recovery After Ischemic Stroke. Stroke. 2011.
  17. Kang, Lee YH, Kim MJ, et al. Transplantation of porcine umbilical cord matrix mesenchymal stem cells in a mouse model of Parkinson's disease. Journal of Tissue Engineering and Regenerative Medicine. 2011.
  18. Kim JY, Kim DH, Kim JH, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-? plaques. Cell Death and Differentiation. 2011.
  19. Zhao Z, Chen Z, Zhao X, et al. Sphingosine-1-phosphate promotes the differentiation of human umbilical cord mesenchymal stem cells into cardiomyocytes under the designated culturing conditions. Journal of Biomedical Science. 2011;18:37
  20. Kim AK, Kim MH, Kim S, et al. Stem-cell Therapy for Peripheral Artery Occlusive Disease. European Journal of Vascular Surgery. 2011.
  21. Jung KH, Uhm YK, Lim YJ, et al. Human umbilical cord blood-derived mesenchymal stem cells improve glucose homeostasis in rats with liver cirrhosis. International Journal of Oncology. 2011.
  22. Sodian R, Schaefermeier P, Abegg-Zips S, et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg. 2010; 89(3):819-28
  23. Kuchment, A. Scientist Grows Jaw Bone From Adult Stem Cells. The Record. March 2010.
  24. Chua SJ, Bielecki R, Yamanaka N, et al. The effect of umbilical cord blood cells on outcomes after experimental traumatic spinal cord injury. Spine (Phila Pa 1976). 2010;35(16):1520-6.
  25. Chua SJ, Bielecki R, Yamanaka N, et al. The effect of umbilical cord blood cells on outcomes after experimental traumatic spinal cord injury. Spine (Phila Pa 1976). 2010;35(16):1520-6.
  26. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Research & Therapy. 2010;12:R210.
  27. Harris D, Schumacher M, LoCascio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proceedings of the National Academy of Sciences. 1992;89:10006-10010.
  28. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373-381.
  29. Bizzetto R, Bonfim C, Rocha V, et al. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. 2011;96(1):134-41.
  30. Butler MG, Menitove JE. Umbilical cord blood banking: an update. J Assist Reprod Genet.2011;28(8):669-76.
  31. Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Journal of Clinical Oncology.2000;18:3256-3261.
  32. McCullough J, Clay M. Reasons for deferral of potential umbilical cord blood donors Transfusion, 2000; 40(1):124-125.
  33. National Marrow Donor Program: ABCs of Marrow or Blood Cell Donation. Available at: http://marrow.org/News/News_Releases/2011/Tionne_T-Boz_Watkins_calls_on_African_Americans_to_step_up_and_donate_marrow.aspx. Accessed November 8, 2011.
  34. Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011;44 Suppl 1:60-9.
  35. Hao Q, Shah AJ, Thiemann FT, et al. A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Blood. 1995;86:3745-3753.
  36. Morettie, P, Hatlapatka, T, Marten, D, et al. Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applicaitons. Adv Biochem Engin/Biotechnology. 2010;123:29-54.
  37. U.S. National Institutes of Health. Clinicaltrials.gov. Umbilical Cord Mesenchymal Stem Cells. Accessed September 15, 2011.
  38. National Marrow Donor Program. Nmdp.org. Trends in Allogeneic Transplants. Accessed September 27, 2011. Source 2: Cord Blood Registry. Cordblood.com. Cord Blood Released for Use by CBR® Clients. Accessed September 27, 2011.
  39. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342(25):1846-1854.
  40. Pazdur R, , Coia L, Hoskins W, et al. Cancer management: a multidisciplinary approach. 1998. Second edition.
  41. Behzad-Behbahani A, Pouransari R, Tabei SZ, et al. Risk of viral transmission via bone marrow progenitor cells versus umbilical cord blood hematopoietic stem cells in bone marrow transplantation. Transplant Proc. 2005;37(7):3211-3212.
  42. Nietfeld JJ, Pasquini MC, Logan BR, et al. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.
  43. Arora M, Nagaraj S,Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB), Biol Blood Marrow Transplant, 2007;13:1145–52.
  44. Linden JV, Preti RA, Dracker R. New York state guidelines for cord blood banking. Journal of Hematotherapy. 1997;6:535-41.
  45. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773-7.
  46. Knudtzon S. In vitro growth of granulocytic colonies from circulating cells in human cord blood. Blood. 1974;43(3):357-61.
  47. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-1178.
  48. Harris D, Schumacher M, LaCascio J, et al. Immunoreactivity of umbilical cord blood and post partum maternal peripheral blood with regard to HLA haploidentical transplantation. Bone Marrow Transplantation. 1994;14:16-38.
  49. Harris DT. Collection, processing and banking of umbilical cord blood for clinical use. The Journal of the Bellevue Obstetrical and Gynecological Society. 2002;18:13-21.
  50. McGuckin CP, Forraz N, Baradez MO, et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Prolif. 2005;38(4):245-55.
  51. Perlow JH. Patient’s knowledge and understanding of umbilical cord blood banking. Journal of Reproductive Medicine. 2006;51(8):642-8.
  52. Hayani A, Lampeter E, Viswanatha D, et al. First report of autologous cord blood transplantation in the treatment of a child with leukemia. Pediatrics. 2007;119:296-300.
  53. Bergstrom L, Hemenway WG, Downs MP. A high risk registry to find congenital deafness. Otolaryngol Clin North Am. 1977;4:369-399.
  54. Billings KR, Kenna MA. Causes of pediatric sensorineural hearing loss: yesterday and today. Arch Otolaryngol Head Neck Surg. 1999 May;125(5):517-21.
  55. Smith RJ, Bale JF Jr, White KR. Sensorineural hearing loss in children. Lancet. 2005;365(9462):879-890.
  56. Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
  57. Schnitzer, Patricia, PH.D., “Prevention of Unintentional Childhood Injuries”, American Academy of Family Physicians, 2006.
  58. Centers for Disease Control and Prevention, “10 Leading Causes of Death, United States, 1997-2007”, WISQARS, National Center for Health Statistics (NCHS), National Vital Statistics System
  59. Marquez de la Plata, Hart et al, National Institutes of Health, “Impact of Age on Long-term Recovery From Traumatic Brain Injury”, Arch Phys Med Rehabilitation, May 2008.
  60. Centers for Disease Control and Prevention, www.cdc.gov/Features/dsCerebralPalsy, accessed February 6, 2012
  61. Bone Marrow and Cord Blood Donation and Transplantation. Available at http://bloodcell.transplant.hrsa.gov/ABOUT/General_FAQs/index.html#1080%20How%20many%20people%20need.
  62. United States Census Bureau. Available at http://www.census.gov/compendia/statab/cats/births_deaths_marriages_divorces.html. Live Births by State and Island Areas: 2009
  63. Liao Y et al. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant. 2012.
  64. Lloyd-Jones d, Adams R, et al. Heart Disease and Stroke Statistics 2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e1-e161.
  65. Roach ES, Golomb MR, Adams R, et al. Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644-2691.
  66. http://www.wbmt.org. "Media Fact Sheet: 1 Million Blood Stem Cell Transplants Worldwide" Accessed 04/02/2013.
  67. Alliance for Regenerative Medicine. 2013 Annual Industry Report.
  68. Allison M, Nature Biotechnology 2012;30(4):304
  69. Brown KS, Selich ML, Range SE, et al. Impact of anticoagulant on processing efficiency. AABB. 2013.
  70. Harris DT, McGaffey A, Brown H. The effect of collection bag anticoagulant on umbilical cord blood stem cell yield. Transfusion. 2008;48(s2):206A.
  71. Harris DT , Glasser L, Badowski MS, Brown H, Brown KS. The effects of anticoagulants on cord blood viability from collection to processing. Blood. 2011;118:Abstract 1923.
  72. Pope B, Mitsakos K, Bilgin A, Hokin B, Grant R. Predicting overall viability of cord blood harvests. Transfusion. 2012 ;52:1079–1085.
  73. Solves P, Mirabet V, Planelles D, et al. Red blood cell depletion with a semiautomated system or hydroxyethyl starch sedimentation for routine cord blood banking: a comparative study. Transfusion. Jun 2005;45(6):867-873.
  74. Harris DT. Expert Opin. Biol. Ther. 2007 Sep;7(9):1311-22.
  75. US Department of Health and Human Services. Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications. US Food and Drug Administration website. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformatioG/Guidances/Blood/UCM187144.pdf. Accessed May 17, 2012.
  76. Department of Health and Human Services Summary of Basis For Approval - http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/newdrugapplicationsndas/ucm082811.pdf
  77. GE Healthcare Life Sciences - http://www.thermogenesis.com/products/cell-processing/axp-autoxpress/
  78. National Institute of Health - Hematopoietic Stem Cells http://stemcells.nih.gov/info/scireport/pages/chapter5.aspx
  79. National Institute of Health - Stem Cell Basics http://stemcells.nih.gov/info/basics/pages/basics4.aspx
  80. Meier C, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatric Research. 2006;59:244-249.
  81. http://www.wbmt.org. "Media Fact Sheet: 1 Million Blood Stem Cell Transplants Worldwide" Accessed 04/02/2013.
  82. clinicaltrials.gov
  83. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013.
  84. Trounson A, Thakar R, Lomax G, Gibbons D. Clinical Trials for Stem Cell Therapies. BMC Medicine. 2011.
  85. Stem Cell Therapeutic and Research Act of 2005, H. R. 2520, 109th Cong (2005). Retrieved from: http://www.gpo.gov/fdsys/pkg/BILLS-109hr2520enr/pdf/BILLS-109hr2520enr.pdf
  86. Rosenthal J, Brown HL, Harris DT. Stem cell recovery following implementation of an automated cord blood processing system in a high volume laboratory. Biol Blood Marrow Transplant. 2008;14(2):42s.; Kurtzberg J, Cairo MS, Fraser JK, et al. Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. Transfusion. 2005;45:842-855.; Papassavas AC, Gioka V, Chatzistamatiou T, et al. A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused hematopoietic progenitor cells in adults. Int Jnl Lab Hem. 2007;1-9.
  87. GE Healthcare Life Sciences. http://www.thermogenesis.com/products/cell-processing/axp-autoxpress/. *AXP and AutoXpress are registered trademarks of ThermoGenesis Corp.

Sign up for free information and special offers. Ready to enroll? Start here, too.